ASCO Annual Meeting 2020 Poster Report of Rivoceranib in Recurrent or Metastatic Adenoid Cystic Carcinoma
This poster was presented at the 2020 ASCO Annual Meeting. It presents a Phase II study evaluating safety and efficacy of rivoceranib in patents with recurrent or metastatic adenoid cystic carcinoma. This phase 2 multi-center aims to evaluate efficacy measured by ORR in ACC patients in the US and South Korea.
To read the full study report download the poster.